Coagulation and fibrinolysis in hyperparathyroidism secondary to Vitamin D Deficiency: the CoViDD study

Coagulation and fibrinolysis in hyperparathyroidism secondary to Vitamin D Deficiency: the CoViDD study - CoViDD study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38482

Enrollment

Registered

2013-07-16

Start date

2013-09-11

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiovasculaire aandoeningen hyperparathyroidism secondary to Vitamin D Deficiency overactivity of the parathyroids because of a shortage of vitamin D

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All consecutive adult patients with moderate-severe vitamin D deficiency, defined as blood levels of 25-OH-D less than 10 ng/ml (25 nmol/l). Controls: patients with vitamin D deficiency already on vitamin D suppletion with a normal PTH and vitamin D

Exclusion criteria

Exclusion criteria: Pregnancy, acute and chronic renal disease, liver cirrhosis, granulomatosis, primary hyperparathyroidism, malabsorption syndromes, Von Willebrand disease, haemophilia, recent bariatric surgery (

Design outcomes

Primary

Measure	Time frame
The following groups of lab markers will be tested: - Overall test: vit. D level, PTH, serum calcium, phosphate, creatinin, albumin, hsCRP - Coagulation markers: von Willebrand factor and ristocetin activity, FVIII, FVII, FIX, FX, FXI, fibrinogen, thrombin - Natural anticoagulant inhibitors: antithrombin, protein C, protein S - Fibrinolysis markers: t-PA, PAI-1, TAFI, D-dimer	—

Secondary

Measure	Time frame
nvt	—

Countries

Netherlands

Outcome results